The simultaneous inhibition of these two regulated cell death pathways represents a highly innovative approach that could treat severe and … Lire la suite
Download pdf Partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate to treat degenerative … Lire la suite
Download PDF Roscoff, France, October 1, 2025 – SeaBeLife, a biotechnology company developing innovative drug candidates intended to block cellular … Lire la suite
download PDF SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues … Lire la suite
Download pdf Orphan designation shows recognition of therapeutic potential of drug candidate SBL01 targeting two regulated cell death pathways … Lire la suite
For the 27th edition of the “Soirée des Carrés”, the Morlaix region’s business club, Domaine de Treuscoat, SeaBeLife and La … Lire la suite
📢 SeaBeLife Biotech will be attending the 8th annual LSX Inv€$tival Showcase Morgane Rousselot, our founder and CEO, and @Jean-Pierre … Lire la suite
Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute … Lire la suite
SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death. Roscoff, May 17th, 2021. SeaBeLife, … Lire la suite
